This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00603239
First received: January 17, 2008
Last updated: March 19, 2015
Last verified: March 2015
January 17, 2008
March 19, 2015
January 2008
July 2009   (Final data collection date for primary outcome measure)
Change in Glycosylated Hemoglobin (HbA1c) [ Time Frame: baseline and 26 weeks ]
Change in HbA1c from baseline to endpoint after 26 weeks of treatment (i.e., HbA1c at endpoint minus HbA1c at baseline)
To test the hypothesis that glycemic control, as measured by the change in HbA1c from baseline to endpoint with exenatide, is superior to placebo in patients with type 2 diabetes and inadequate glycemic control taking a TZD alone or a TZD plus metformin. [ Time Frame: 26 weeks ]
Complete list of historical versions of study NCT00603239 on ClinicalTrials.gov Archive Site
  • Percentage of Patients Achieving HbA1c <= 7% [ Time Frame: 26 weeks ]
    Percentage of intent-to-treat (ITT) patients who had HbA1c > 7% at baseline that decreased to <= 7% at endpoint (Week 26 or early discontinuation)
  • Percentage of Patients Achieving HbA1c <= 6.5% [ Time Frame: 26 weeks ]
    Percentage of ITT patients who had achieved HbA1c <= 6.5% at endpoint (Week 26 or early discontinuation)
  • Change in Fasting Serum Glucose (FSG) [ Time Frame: baseline and 26 weeks ]
    Change in FSG from baseline to endpoint (26 weeks)
  • Change in Body Weight [ Time Frame: baseline and 26 weeks ]
    Change in body weight from baseline to endpoint (26 weeks)
  • Change in Waist Circumference [ Time Frame: baseline and 26 weeks ]
    Change in waist circumference from baseline to endpoint (26 weeks)
  • Change in Beta-cell Function [ Time Frame: baseline and 26 weeks ]
    Change in homeostatic model assessment-beta cell (HOMA-B) from baseline to endpoint (Week 26) (outcome measure is presented as the ratio of endpoint HOMA-B divided by baseline HOMA-B). HOMA-B is a measure of pancreatic beta-cell function.
  • Change in Insulin Sensitivity. [ Time Frame: baseline and 26 weeks ]
    Change in homeostatic model assessment-insulin sensitivity (HOMA-S) from baseline to endpoint (26 weeks) (outcome measure is presented as the ratio of endpoint HOMA-S divided by baseline HOMA-S).
  • Number of Subjects Who Experienced an Episode of Minor Hypoglycemia [ Time Frame: 26 weeks ]
    Overall number of subjects who experienced an episode of minor hypoglycemia.
  • Change in Impact of Weight on Quality of Life (IWQOL)-Lite Score [ Time Frame: baseline and 26 weeks ]
    IWQOL-Lite analysis of change from baseline to endpoint (26 weeks). IWQOL-Lite is a 31-item questionnaire, assessing the domains of physical function, self-esteem, sexual life, public distress, and work. Response categories for each item range from 1 = "never true" to 5 = "always true."
  • Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score [ Time Frame: baseline and 26 weeks ]
    EQ-5D Score - change from baseline to endpoint (26 weeks). EQ-5D is a 5-item questionnaire used to characterize current health states. The tool and accompanying visual analog scale (VAS) assess 5 domains of quality of life, including mobility, self-care, usual activity, pain, and anxiety/depression. Weights are used to score the responses to the 5 domains, with 3 options possible in each domain: extreme problems, some/moderate problems, or no problems. Scores range from 0 to 1, with a score of 1 representing a perfect health state.
  • To compare exenatide and placebo groups with respect to: proportion of patients achieving HbA1c ≤7% and ≤6.5%; fasting serum glucose; body weight; waist circumference. [ Time Frame: 26 weeks ]
  • To compare exenatide and placebo groups with respect to: beta-cell function and insulin sensitivity; health outcome measures; incidence and rate of hypoglycemic events; safety and tolerability. [ Time Frame: 26 weeks ]
Not Provided
Not Provided
 
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: exenatide
    subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
    Other Name: Byetta
  • Drug: placebo
    subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
  • Experimental: Exenatide twice daily (BID)
    Intervention: Drug: exenatide
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
165
July 2009
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with type 2 diabetes
  • If treated with a thiazolidinedione (TZD) alone, the TZD dose must have been stable for at least 120 days
  • The dose of TZD must be: Rosiglitazone (≥4 mg/day) or pioglitazone (≥30 mg/day)
  • The metformin dose has been stable for at least 90 days
  • Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 10.0%, inclusive.
  • Have a body mass index (BMI): 25 kg/m2 < BMI < 45 kg/m2.

Exclusion Criteria:

  • Have participated in this study previously or any other study using exenatide (AC2993/LY2148568) or glucagon-like peptide-1 (GLP-1) analogs, or have been previously treated with exenatide or GLP-1 analogs
  • Have participated in an interventional medical, surgical, or pharmaceutical study (a study in which an experimental, drug, medical, or surgical treatment was given) within 30 days of screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
  • Have been treated with exogenous insulin for more than 1 week within the 2 months prior to screening
  • Used drugs for weight loss (e.g., orlistat, rimonabant, sibutramine, or similar over-the-counter medications) within 3 months prior to screening.
  • Are currently treated with any of the following excluded medications:

    • Sulfonylurea or meglitinide derivatives (e.g., repaglinide or nateglinide) within 3 months prior to screening
    • Alpha-glucosidase inhibitor (e.g., miglitol or acarbose) within 3 months of screening
    • Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin or vildagliptin) within 3 months prior to screening
    • Pramlintide acetate injection within 3 months prior to screening
    • Drugs that directly affect gastrointestinal motility, including, but not limited to: Metoclopramide, cisapride, and chronic macrolide antibiotics
    • Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding study start
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Mexico,   Romania,   South Africa,   United States
 
 
NCT00603239
H8O-MC-GWCG
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Eli Lilly and Company
Study Director: Chief Medical Officer, MD Eli Lilly and Company
AstraZeneca
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP